EuroEyes International Eye Clinic Future Growth
Future criteria checks 4/6
EuroEyes International Eye Clinic is forecast to grow earnings and revenue by 26.7% and 16.2% per annum respectively while EPS is expected to grow by 3.1% per annum.
Key information
26.7%
Earnings growth rate
3.1%
EPS growth rate
Healthcare earnings growth | 19.1% |
Revenue growth rate | 16.2% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
EuroEyes International Eye Clinic's (HKG:1846) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Sep 05EuroEyes International Eye Clinic (HKG:1846) Is Reducing Its Dividend To HK$0.0489
Jun 09EuroEyes International Eye Clinic (HKG:1846) Is Paying Out Less In Dividends Than Last Year
May 09Earnings Tell The Story For EuroEyes International Eye Clinic Limited (HKG:1846) As Its Stock Soars 27%
May 06EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489
Apr 25EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489
Mar 31What Is EuroEyes International Eye Clinic Limited's (HKG:1846) Share Price Doing?
Nov 21Analysts Have Just Cut Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Estimates By 15%
Sep 08EuroEyes International Eye Clinic Limited (HKG:1846) Shares Could Be 24% Below Their Intrinsic Value Estimate
Jul 31Analysts Just Made A Major Revision To Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Forecasts
Apr 25There Are Reasons To Feel Uneasy About EuroEyes International Eye Clinic's (HKG:1846) Returns On Capital
Dec 05EuroEyes International Eye Clinic (HKG:1846) Will Pay A Larger Dividend Than Last Year At HK$0.099
May 26EuroEyes International Eye Clinic's (HKG:1846) Upcoming Dividend Will Be Larger Than Last Year's
May 12EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Increased To HK$0.099
Apr 27EuroEyes International Eye Clinic (HKG:1846) Is Increasing Its Dividend To HK$0.099
Apr 08Slowing Rates Of Return At EuroEyes International Eye Clinic (HKG:1846) Leave Little Room For Excitement
Mar 07Is Now An Opportune Moment To Examine EuroEyes International Eye Clinic Limited (HKG:1846)?
Jan 18The Returns At EuroEyes International Eye Clinic (HKG:1846) Aren't Growing
Nov 02There Are Reasons To Feel Uneasy About EuroEyes International Eye Clinic's (HKG:1846) Returns On Capital
May 20Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,126 | 216 | 146 | 352 | 1 |
12/31/2025 | 902 | 151 | 141 | 254 | 2 |
12/31/2024 | 794 | 120 | 103 | 199 | 2 |
6/30/2024 | 736 | 108 | 111 | 203 | N/A |
3/31/2024 | 725 | 120 | 107 | 197 | N/A |
12/31/2023 | 714 | 131 | 102 | 192 | N/A |
9/30/2023 | 678 | 121 | 116 | 192 | N/A |
6/30/2023 | 641 | 110 | 129 | 193 | N/A |
3/31/2023 | 626 | 100 | 141 | 201 | N/A |
12/31/2022 | 610 | 89 | 153 | 209 | N/A |
9/30/2022 | 620 | 102 | 163 | 224 | N/A |
6/30/2022 | 629 | 115 | 172 | 238 | N/A |
3/31/2022 | 631 | 124 | 201 | 256 | N/A |
12/31/2021 | 633 | 134 | 229 | 273 | N/A |
9/30/2021 | 619 | 123 | 200 | 245 | N/A |
6/30/2021 | 605 | 113 | 171 | 217 | N/A |
3/31/2021 | 539 | 89 | 105 | 148 | N/A |
12/31/2020 | 474 | 66 | 40 | 78 | N/A |
9/30/2020 | 443 | 38 | 28 | 59 | N/A |
6/30/2020 | 412 | 10 | 16 | 39 | N/A |
3/31/2020 | 426 | 5 | 8 | 34 | N/A |
12/31/2019 | 430 | -3 | 35 | 64 | N/A |
3/31/2019 | 389 | 23 | 74 | 91 | N/A |
12/31/2018 | 385 | 34 | 137 | 157 | N/A |
12/31/2017 | 347 | 82 | N/A | 83 | N/A |
12/31/2016 | 248 | 19 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1846's forecast earnings growth (26.7% per year) is above the savings rate (2.3%).
Earnings vs Market: 1846's earnings (26.7% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).
High Growth Earnings: 1846's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1846's revenue (16.2% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 1846's revenue (16.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1846's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 13:20 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
EuroEyes International Eye Clinic Limited is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Wai Chak Yuen | BOCI Research Ltd. |
Yichi Zhang | China International Capital Corporation Limited |
Yue-Kwong Lui | Jefferies LLC |